The “Partnerships, Licenses, Investments, Mergers and Acquisitions Deals and Trends in the Pharmaceutical Industry – Q1 2020” Report was added ResearchAndMarkets.com Offer.

The Partnerships, Licenses, Investments, Mergers and Acquisitions – Pharmaceutical Businesses and Trends – Q1 2020 report is an important source of data and trend analysis on partnerships, licenses, mergers and acquisitions (M&A) and financing in the the pharmaceutical industry.

The report provides detailed information on partnership and licensing transactions, mergers and acquisitions, stock / debt offers, private equity and venture finance registered in the pharmaceutical industry in Q2 2020. The report provides detailed comparative data on the number of transactions and their value in the last quarter of five, broken down by business type, different therapy areas and regions. The report also includes information on the leading financial advisory firms in the pharmaceutical industry.

scope

  • Analysis of market trends for the pharmaceutical industry in the global arena.

  • Review of deal trends in cardiovascular, central nervous system, dermatology, ear, nose and throat diseases, gastrointestinal, urogenital and sex hormones, hematological disorders, hormonal disorders, immunology, infectious diseases, male health, metabolic disorders, mouth – and dental diseases, segments of the musculoskeletal system, oncology, ophthalmology, respiratory tract, toxicology and women’s health.

  • Analysis of partnerships, licenses, mergers and acquisitions, equity / debt, private equity and risk finance deals in the pharmaceutical industry.

  • Analysis of therapy areas that are very active in terms of venture capital financing, partnerships, licensing agreements, stock / debt offerings, and mergers and acquisitions.

  • Analysis of deals based on different payment modes, including prepayments and milestone payments, mainly in partnerships and licensing agreements in the pharmaceutical industry.

  • Analysis of partnership and license agreements based on the clinical development stage of products.

  • Summary of global pharmaceutical deals in the five quarters.

  • There was information about the top deals in the pharmaceutical industry.

  • The regions covered include North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa.

  • Financial advisor rankings on mergers and acquisitions and stock / debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse and Goldman Sachs.

Main topics covered:

The story goes on

1 Table of Contents

1.1 List of tables

1.2 List of Figures

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2020

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2nd quarter 2020

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2020

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2020

2.4 Pharma & Healthcare, Global, Top Deals, 2nd Quarter 2020

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type

3.1 Pharma & Healthcare, Global, M & A, Q2 2020

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2nd quarter 2020

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2nd quarter 2020

3.5 Pharma & Healthcare, Global, Private Equity Deals, Q2 2020

4 Pharmaceuticals & Healthcare, Global, Partnership Agreement, Q2 2020

4.1 Pharma & Healthcare, Global, Partnership Agreement, Q2 2020

4.2 Pharmaceuticals and Healthcare, Global, Partnership Agreement, by Therapy Area, Q2 2019 – Q2 2020

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, after prepayments and milestone payments and deal values ​​(in USD million), Q2 2020

4.4 Pharmaceuticals and Healthcare, Global, Partnership Agreement, By Area of ​​Therapy, By Prepayments & Milestone Payments, And Goodwill (In $ MILLION) Q2 2019 – Q2 2020

4.5 Pharmaceuticals & Healthcare, Global, Partnership Agreement, by Phase, Number of Deals, Q2 2019 – Q2 2020

4.6 Pharmaceuticals and Healthcare, Global, Partnership Agreements, by Stage, Goodwill (USD MILLION), Q2 2019 – Q2 2020

4.7 Pharmaceuticals and Healthcare, Global, Partnership Agreement, By Stages, By Prepayments & Milestone Payments, And Goodwill (USD MILLION) Q2 2019 – Q2 2020

5 Pharmaceuticals & Healthcare, Global, License Agreements, Q2 2020

5.1 Pharma & Healthcare, Global, License Agreements, Q2 2020

5.2 Pharmaceuticals & Healthcare, Global, License Agreement, Prepayments & Milestone Payments, and Goodwill (USD MILLION) Q2 2019 – Q2 2020

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement, by Therapy Area, Total Business Value (USD MILLION), Q2 2019 – Q2 2020

5.4 Pharmaceuticals & Healthcare, Global, License Agreement, by Therapy Area, Prepayments for Milestone Payments (USD MILLION), Q2 2019 – Q2 2020

5.5 Pharmaceuticals & Healthcare, Global, License Agreement, by Phase, Total Deals, Q2 2019 – Q2 2020

5.6 Pharmaceuticals & Healthcare, Global, License Agreement, by Stage, Total Business Values ​​(USD MILLION), Q2 2019 – Q2 2020

5.7 Pharmaceuticals & Healthcare, Global, License Agreement, by Phases, Prepayments for Milestone Payments (in MILLION USD), Q2 2019 – Q2 2020

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2020

6.2 Pharmaceuticals and Healthcare, Global Central Nervous System Offerings, Q2 2020

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2020

6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2020

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Offers, 2nd Quarter 2020

6.6 Pharma & Healthcare, Global, Cardiovascular Deals, Q2 2020

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2020

6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2020

6.9 Pharma & Healthcare, Global, Respiratory Deals, Q2 2020

6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2020

7 Deal Summary by Geography

7.1 Pharmaceuticals & Healthcare North America Region Deals Q2 2020

7.2 Pharma & Healthcare, Europe Region, Offers, 2nd Quarter 2020

7.3 Pharma & Healthcare, Asia Pacific, Deals, Q2 2020

7.4 Pharma & Healthcare, Rest of World, Deals, 2nd Quarter 2020

8 Pharmaceuticals & Healthcare, Global, Top Advisors

8.1 Pharma & Healthcare, Global Top Financial Advisors, M&A, Q2 2019 – Q2 2020

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisor, Stock Offerings, Q2 2019 – Q2 2020

For more information on this report, see https://www.researchandmarkets.com/r/uvtqsy

View source version on businesswire.com: https://www.businesswire.com/news/home/20210402005173/de/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For EST office hours, call 1-917-300-0470
For US / CAN Toll Free, call 1-800-526-8630
For GMT office hours, call + 353-1-416-8900